Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2021 Sep 29;88(6):1009–1020. doi: 10.1007/s00280-021-04357-4

Table 3.

Summary of crizotinib exposure values

Occasion Dosage (mg/m2) CMAX (ng/mL) AUC0-t (h·ng/mL)
Single-dose as single agent 100 65.4 (41.9–89.8) 1010 (567–1495)
130 79.6 (74.7–134) 1527 (1044–2497)
165 163 (57.0–550) 2391 (797–8960)
215 301 (72.2–636) 4296 (1398–9604)
Steady-state as single agent 100 373 (348–445) 5608 (4552–7987)
130 401 (250–620) 6344 (4659–10088)
Steady-state in combination with dasatinib 100 101 (98.7–223) 1109 (790–2243)
165 184 (90.6–457) 2870 (1422–6443)
215 308 (97.3–419) 4939 (1689–6537)

Data are reported as median (range)

Area under the curve (AUC): time t refers to 48h for single-dose data and to 24h for steady-state data.